查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1455696

非结核分枝桿菌市场，按药物类别、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Nontuberculous Mycobacteria Market, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023年非结核分枝桿菌市场规模为93.2034亿美元，2024年至2032年复合CAGR为3.14%。

非结核分枝桿菌市场-市场动态

非结核分枝桿菌肺部疾病的发生率不断增加，特别是在全球老年人口中，预计将推动市场的成长。

全球人口老化导致老年人数量显着增加。由于年龄是 NTM 肺病的危险因素，预计老年人口的增加将导致该疾病发病率的上升，从而对诊断和治疗解决方案产生更高的需求。医疗保健提供者和患者对 NTM 肺病认识的提高以及获得医疗服务的机会的增加，导致诊断和治疗率的提高。根据英国国家卫生服务局的数据，2021 年，呼吸系统疾病（作为主要原因或相关原因）的死亡率在老年人中更为普遍（73% 的呼吸系统死亡发生在75 岁及以上的个体中，而75 岁及以上的个体中，这一比例为67%）。总死亡人数）。此外，诊断技术的进步，例如高通量定序和增强培养方法，可能会为市场带来成长机会。然而，高昂的治疗成本可能会阻碍市场的成长。

非结核分枝桿菌市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 3.14% 左右的CAGR成长

根据药物类别细分，预计口服抗生素将在 2023 年显示最大的市场份额

按地区划分，北美是 2023 年的主要收入来源

非结核分枝桿菌市场-細項分析：

全球非结核分枝桿菌市场依据药物类别、配销通路和区域进行细分。

根据药物类别，市场分为四类：口服抗生素、静脉注射抗生素、抗噁心药物和雾化抗生素。口服抗生素类别在市场上占有最大份额。 NTM 相关疾病的流行、现有抗生素的有效性、治疗方案和监管授权等各种因素都会影响用于治疗非结核分枝桿菌 (NTM) 感染的口服抗生素市场。

根据配销通路，市场分为三个部分：医院药房、零售药房和网路药房。生产抗生素和其他治疗 NTM 感染药物的製药公司透过传统的药品分销管道分销其产品。

非结核分枝桿菌市场 - 地理洞察

该市场在地理上遍布各个地区，分别是北美、拉丁美洲、欧洲、亚太地区、中东和非洲。这些区域根据参与商业活动的国家进一步划分。预计该市场的成长将由北美主导，这主要是由于开发新药物的研究力度加大以及医疗费用的上升。专注于发现 NTM 感染的新抗生素和治疗方案的研发工作显着激增。在美国，2021 年医疗支出成长 2.7%，达到 4.3 兆美元，即人均 12, 914 美元。这一增长率明显低于美国医学会表示的2020年（10.3%）。欧洲是该市场的第二大地区，这主要是由于传染病发病率的上升。

非结核分枝桿菌市场-竞争格局：

专门开发抗生素和其他 NTM 感染治疗药物的各种製药公司是该市场的主要竞争对手。他们根据产品有效性、安全性和定价等因素以及确保市场准入的策略进行竞争。竞争还可能涉及创造对 NTM 物种具有更好活性的新抗生素或提高患者依从性和治疗效果的配方。 NTM 市场的竞争延伸到临床开发管道，公司的目标是推出新的治疗方法或扩大现有产品的适应症。总体而言，NTM 市场的竞争由产品差异化、临床开发工作、监管因素、市场准入计划、研究和创新以及合作决定。

最近的发展：

2020年6月16日，诺华ILARIS（canakinumab）获得美国食品药物管理局（FDA）核准用于治疗成人史蒂尔氏症（AOSD）的新适应症。 FDA 核准治疗 2 岁及以上的活动性史蒂尔病，包括系统性幼年特发性关节炎 (SJIA) 和 AOSD。

目录

第一章：非结核分枝桿菌市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的非结核分枝桿菌市场片段
    • 按配销通路的非结核分枝桿菌市场片段
    • 按国家/地区分類的非结核分枝桿菌市场片段
    • 按地区分類的非结核分枝桿菌市场片段
  • 竞争洞察

第 3 章：非结核分枝桿菌主要市场趋势

  • 非结核分枝桿菌市场驱动因素
    • 市场驱动因素的影响分析
  • 非结核分枝桿菌市场限制
    • 市场限制影响分析
  • 非结核分枝桿菌市场机会
  • 非结核分枝桿菌市场未来趋势

第 4 章：非结核分枝桿菌产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：非结核分枝桿菌市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：非结核分枝桿菌市场格局

  • 2023 年非结核分枝桿菌市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：非结核分枝桿菌市场 - 按药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 口服抗生素
    • 静脉注射抗生素
    • 抗噁心
    • 雾化抗生素

第 8 章：非结核分枝桿菌市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 9 章：非结核分枝桿菌市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美非结核分枝桿菌主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲非结核分枝桿菌主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区非结核分枝桿菌主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲非结核分枝桿菌主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲非结核分枝桿菌主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析 - 非结核分枝桿菌产业

  • 竞争仪表板
  • 公司简介
    • Insmed, RedHill Biopharma Ltd
    • Novartis AG
    • Paratek Pharmaceuticals Inc
    • Janssen
    • RevImmune
    • Nobelpharma Co Ltd
    • Others

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV2359

REPORT HIGHLIGHT

Nontuberculous Mycobacteria Market size was valued at USD 9,320.34 Million in 2023, expanding at a CAGR of 3.14% from 2024 to 2032.

Nontuberculous mycobacteria are a collection of bacteria that naturally exist in soil, water, and dust all over the world. Non-tuberculous mycobacteria (NTM) refers to a group of over 190 species of Mycobacterium, excluding Mycobacterium tuberculosis and Mycobacterium leprae. These microorganisms are present everywhere in the environment, especially in soil and water sources, and are increasingly being recognized as a cause of human diseases. Non-tuberculous mycobacteria can infect not only individuals with weakened immune systems but also those who are otherwise healthy. The diagnosis and management of NTM infections pose numerous challenges.

Nontuberculous Mycobacteria Market- Market Dynamics

Increasing occurrence of nontuberculous mycobacterial lung illness, particularly amongst the older population worldwide, is projected to propel market's growth.

The aging global population is experiencing a significant rise in the number of elderly individuals. Due to the fact that age is a risk factor for NTM lung disease, the increasing elderly demographic is anticipated to contribute to the growing incidence of the illness, thereby creating a higher demand for diagnostic and therapeutic solutions. The improved awareness among healthcare providers and patients regarding NTM lung disease, along with better access to healthcare services, has resulted in increased rates of diagnosis and treatment. According to the National Health Service, in 2021, the mortality rate from respiratory conditions (as either the primary or associated cause) was more prevalent among older individuals (73% of respiratory deaths occurred in individuals aged 75 and above, compared to 67% for total deaths). Additionally, advancements in diagnostic techniques, such as high-throughput sequencing and enhanced culture methods, could present growth opportunities for the market. Nevertheless, the high cost of treatment may impede the market's growth.

Nontuberculous Mycobacteria Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.14% over the forecast period (2024-2032)

Based on Drug Class segmentation, Oral Antibiotics was predicted to show maximum market share in the year 2023

On the basis of region, North America was the leading revenue generator in 2023

Nontuberculous Mycobacteria Market- Segmentation Analysis:

The Global Nontuberculous Mycobacteria Market is segmented on the basis of Drug Class, Distribution Channel, and Region.

The market is segmented into four categories according to Drug Class: Oral Antibiotics, IV Antibiotics, Anti-Nausea, and Nebulized Antibiotics. The Oral Antibiotics category holds the largest share in the market. Various factors such as the prevalence of NTM-related diseases, the effectiveness of existing antibiotics, treatment protocols, and regulatory authorizations impact the market for oral antibiotics utilized in treating nontuberculous mycobacteria (NTM) infections.

The market is categorized into three segments according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Pharmaceutical companies that manufacture antibiotics and other medications for NTM infections distribute their products through conventional pharmaceutical distribution channels.

Nontuberculous Mycobacteria Market- Geographical Insights

This market is geographically spread across various regions, namely North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increased research efforts in developing new medications and the rising healthcare expenses. There is a notable surge in research and development endeavors focused on discovering new antibiotics and treatment regimens for NTM infections. In the United States, health spending witnessed a 2.7% increase in 2021, reaching USD4.3 trillion or USD12, 914 per capita. This growth rate is significantly lower than that of 2020 (10.3%), stated by the American Medical Association. Europe holds the second-largest region for this market, primarily due to the rising rates of infectious illnesses.

Nontuberculous Mycobacteria Market- Competitive Landscape:

Various pharmaceutical companies specializing in the development of antibiotics and other therapeutics for NTM infections are the main competitors in this market. They compete based on factors like product effectiveness, safety, and pricing, as well as strategies to secure market access. Competition may also involve creating new antibiotics with better activity against NTM species or formulations that improve patient adherence and outcomes. The rivalry in the NTM market extends to the clinical development pipeline, where companies aim to introduce new treatments or expand existing product indications. Overall, competition in the NTM market is shaped by product differentiation, clinical development efforts, regulatory factors, market access plans, research and innovation, and collaborations.

Recent Developments:

On June 16, 2020, Novartis ILARIS (canakinumab) was approved by the US Food and Drug Administration (FDA) for a new indication to treat Adult-Onset Still's Disease (AOSD). The FDA granted approval for active Still's disease, which includes both systemic juvenile idiopathic arthritis (SJIA) and AOSD, in patients aged 2 years and older.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Insmed, RedHill Biopharma Ltd

Novartis AG

Paratek Pharmaceuticals Inc

Janssen

RevImmune

Nobelpharma Co Ltd

Others

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Oral Antibiotics
  • IV Antibiotics
  • Anti Nausea
  • Nebulized Antibiotics

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Nontuberculous Mycobacteria Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Nontuberculous Mycobacteria Market Snippet by Drug Class
    • 2.1.2.Nontuberculous Mycobacteria Market Snippet by Distribution Channel
    • 2.1.3.Nontuberculous Mycobacteria Market Snippet by Country
    • 2.1.4.Nontuberculous Mycobacteria Market Snippet by Region
  • 2.2.Competitive Insights

3.Nontuberculous Mycobacteria Key Market Trends

  • 3.1.Nontuberculous Mycobacteria Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Nontuberculous Mycobacteria Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Nontuberculous Mycobacteria Market Opportunities
  • 3.4.Nontuberculous Mycobacteria Market Future Trends

4.Nontuberculous Mycobacteria Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Nontuberculous Mycobacteria Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Nontuberculous Mycobacteria Market Landscape

  • 6.1.Nontuberculous Mycobacteria Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Nontuberculous Mycobacteria Market - By Drug Class

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2.Oral Antibiotics
    • 7.1.3.IV Antibiotics
    • 7.1.4.Anti-Nausea
    • 7.1.5.Nebulized Antibiotics

8.Nontuberculous Mycobacteria Market - By Distribution Channel

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 8.1.2.Hospital pharmacies
    • 8.1.3.Retail pharmacies
    • 8.1.4.Online pharmacies

9.Nontuberculous Mycobacteria Market- By Geography

  • 9.1.Introduction
    • 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2.North America
    • 9.2.1.Overview
    • 9.2.2.Nontuberculous Mycobacteria Key Manufacturers in North America
    • 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4.North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.2.5.North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.6.U.S.
      • 9.2.6.1.Overview
      • 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3.U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.2.6.4.U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.7.Canada
      • 9.2.7.1.Overview
      • 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3.Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.2.7.4.Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.Europe
    • 9.3.1.Overview
    • 9.3.2.Nontuberculous Mycobacteria Key Manufacturers in Europe
    • 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4.Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.5.Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.6.Germany
      • 9.3.6.1.Overview
      • 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3.Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.6.4.Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.7.Italy
      • 9.3.7.1.Overview
      • 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3.Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.7.4.Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.8.United Kingdom
      • 9.3.8.1.Overview
      • 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3.United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.8.4.United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.9.France
      • 9.3.9.1.Overview
      • 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3.France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.9.4.France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.10.Russia
      • 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2.Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.10.3.Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.11.Netherlands
      • 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2.Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.11.3.Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.12.Sweden
      • 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2.Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.12.3.Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.13.Poland
      • 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2.Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.13.3.Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.14.Rest of Europe
      • 9.3.14.1.Overview
      • 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3.Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.14.4.Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.Asia Pacific (APAC)
    • 9.4.1.Overview
    • 9.4.2.Nontuberculous Mycobacteria Key Manufacturers in Asia Pacific
    • 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4.Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.5.Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.6.India
      • 9.4.6.1.Overview
      • 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3.India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.6.4.India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.7.China
      • 9.4.7.1.Overview
      • 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3.China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.7.4.China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.8.Japan
      • 9.4.8.1.Overview
      • 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3.Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.8.4.Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.9.South Korea
      • 9.4.9.1.Overview
      • 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3.South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.9.4.South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.10.Australia
      • 9.4.10.1.Overview
      • 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3.Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.10.4.Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.11.Thailand
      • 9.4.11.1.Overview
      • 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3.Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.11.4.Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.12.Indonesia
      • 9.4.12.1.Overview
      • 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3.Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.12.4.Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.13.Philippines
      • 9.4.13.1.Overview
      • 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3.Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.13.4.Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.14.Rest of APAC
      • 9.4.14.1.Overview
      • 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3.Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.14.4.Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.Latin America
    • 9.5.1.Overview
    • 9.5.2.Nontuberculous Mycobacteria Key Manufacturers in Latin America
    • 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4.Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.5.Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.6.Brazil
      • 9.5.6.1.Overview
      • 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3.Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.6.4.Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.7.Mexico
      • 9.5.7.1.Overview
      • 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3.Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.7.4.Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.8.Argentina
      • 9.5.8.1.Overview
      • 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3.Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.8.4.Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.9.Colombia
      • 9.5.9.1.Overview
      • 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3.Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.9.4.Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.10.Rest of LATAM
      • 9.5.10.1.Overview
      • 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3.Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.10.4.Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.Middle East and Africa
    • 9.6.1.Overview
    • 9.6.2.Nontuberculous Mycobacteria Key Manufacturers in Middle East and Africa
    • 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4.Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.5.Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.6.Saudi Arabia
      • 9.6.6.1.Overview
      • 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3.Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.6.4.Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.7.United Arab Emirates
      • 9.6.7.1.Overview
      • 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3.United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.7.4.United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.8.Israel
      • 9.6.8.1.Overview
      • 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3.Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.8.4.Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.9.Turkey
      • 9.6.9.1.Overview
      • 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3.Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.9.4.Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.10.Algeria
      • 9.6.10.1.Overview
      • 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3.Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.10.4.Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.11.Egypt
      • 9.6.11.1.Overview
      • 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3.Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.11.4.Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.12.Rest of MEA
      • 9.6.12.1.Overview
      • 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3.Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.12.4.Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Nontuberculous Mycobacteria Industry

  • 10.1.Competitive Dashboard
  • 10.2.Company Profiles
    • 10.2.1.Insmed, RedHill Biopharma Ltd
    • 10.2.2.Novartis AG
    • 10.2.3.Paratek Pharmaceuticals Inc
    • 10.2.4.Janssen
    • 10.2.5.RevImmune
    • 10.2.6.Nobelpharma Co Ltd
    • 10.2.7.Others

11.360 Degree Analyst View

12.Appendix

  • 12.1.Research Methodology
  • 12.2.References
  • 12.3.Abbreviations
  • 12.4.Disclaimer
  • 12.5.Contact Us

List of Tables

  • TABLE List of data Drug Classs
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Nontuberculous Mycobacteria Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Nontuberculous Mycobacteria Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Nontuberculous Mycobacteria Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Nontuberculous Mycobacteria Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Nontuberculous Mycobacteria Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Nontuberculous Mycobacteria Market, by Region 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)